ReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 18:29:43时区推断·⟳ 抓取 18:33:23·⚡ 决策 07-23 21:09:02 +2h35m·95.9 天前
赛默飞二季度收入和调整后EPS超预期，盘前涨幅回落
赛默飞（TMO.US）二季度收入119.9亿美元高于LSEG一致预期117.0亿美元，调整后EPS 6.03美元高于预期5.71美元，反映生命科学工具需求改善。
📄 原文Reuters↗ 原文
Thermo Fisher Scientific (TMO.N) beat Wall Street estimates for second-quarter profit and revenue on Thursday, as impro…
不做 赛默飞（TMO.US）
已排期财报小幅超预期但无明确全年指引上修，且盘前涨幅已从路透报道时约4%至5%回落到+0.57%，对1956亿美元市值主标的短线edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司此前已公告将于2026-07-23盘前发布二季度业绩并在08:30 ET召开电话会，财报日历本身可预期。
- 路透报道赛默飞二季度收入和调整后EPS均超预期，客户需求改善带动所有业务板块销售增长。市场反应:报道时称赛默飞盘前上涨近4%至5%。
- 2026-07-23 09:07 ET市场反应Futu非一手实时报价显示赛默飞（TMO.US）盘前价格526.46美元，较前收523.46美元仅上涨0.57%，初始涨幅已明显收窄。市场反应:TMO.US +0.57%。
关键理由
- 赛默飞（TMO.US）二季度收入119.9亿美元高于LSEG一致预期117.0亿美元，调整后EPS 6.03美元高于预期5.71美元，反映生命科学工具需求改善。
- 本次是已排期的盘前财报，属于大市值公司常规业绩披露，超预期幅度约2.5%收入和5.6%EPS，未见明确全年指引上修。
- 盘前报价仅较前收上涨0.57%，明显低于路透首发时提到的近4%至5%涨幅，说明初始反应已快速降温。
主要风险
- 生命科学工具板块需求修复仍有分化，同行Danaher虽盈利超预期但下调全年核心收入增长展望并披露生物技术业务收入低预期。
- 赛默飞市值约1956亿美元，单季小幅超预期不足以形成短线高弹性重定价。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中赛默飞本次二季度业绩的有效旧闻或深度解读，未提供可证明全年指引大幅上修的证据。
检索:Thermo Fisher Q2 2026 earnings revenue profit demand guidance biotech spending - 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
路透报道中提到Danaher下调全年核心收入增长展望且生物技术业务收入低预期，说明行业需求修复仍不均衡。
检索:Danaher Q2 2026 biotechnology revenue outlook cut Thermo Fisher demand 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,602 字
Thermo Fisher Scientific (TMO.N) beat Wall Street estimates for second-quarter profit and revenue on Thursday, as improving customer demand lifted sales across all its business segments.
Shares of the Waltham, Massachusetts-based company were up nearly 4% in premarket trading.
The life sciences tools market has shown signs of improvement as biotech and pharmaceutical companies increase spending on research and manufacturing after a prolonged post-pandemic slowdown. Thermo Fisher said customer activity across its markets continued to strengthen.
"Our end markets continue to strengthen and we're making great progress enhancing our capabilities,” CEO Marc Casper said.
Thermo Fisher’s laboratory products and biopharma services segment, which supports clinical trials and drug manufacturing, posted a near 12% rise in revenue to $6.69 billion.
The life-sciences solutions segment, which supplies products used in biological research and drug production, recorded an increase of about 13% in revenue to $2.82 billion.
The company's quarterly revenue grew 10% to $11.99 billion, above analysts' estimate of $11.70 billion, according to data compiled by LSEG.
Peer Danaher (DHR.N) also beat quarterly profit estimates and raised its annual profit outlook. However, it cut its full-year core revenue growth outlook earlier this week due to weaker respiratory testing revenue and reported lower-than-expected revenue in its biotechnology business.
Thermo Fisher posted second-quarter adjusted earnings of $6.03 per share, above analysts' average estimate of $5.71 per share.
Shares of the Waltham, Massachusetts-based company were up nearly 4% in premarket trading.
The life sciences tools market has shown signs of improvement as biotech and pharmaceutical companies increase spending on research and manufacturing after a prolonged post-pandemic slowdown. Thermo Fisher said customer activity across its markets continued to strengthen.
"Our end markets continue to strengthen and we're making great progress enhancing our capabilities,” CEO Marc Casper said.
Thermo Fisher’s laboratory products and biopharma services segment, which supports clinical trials and drug manufacturing, posted a near 12% rise in revenue to $6.69 billion.
The life-sciences solutions segment, which supplies products used in biological research and drug production, recorded an increase of about 13% in revenue to $2.82 billion.
The company's quarterly revenue grew 10% to $11.99 billion, above analysts' estimate of $11.70 billion, according to data compiled by LSEG.
Peer Danaher (DHR.N) also beat quarterly profit estimates and raised its annual profit outlook. However, it cut its full-year core revenue growth outlook earlier this week due to weaker respiratory testing revenue and reported lower-than-expected revenue in its biotechnology business.
Thermo Fisher posted second-quarter adjusted earnings of $6.03 per share, above analysts' average estimate of $5.71 per share.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。